| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010340839 |
| P356 | DOI | 10.1186/1477-7827-1-65 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC239893 |
| https://rbej.biomedcentral.com/track/pdf/10.1186/1477-7827-1-65 | ||
| https://europepmc.org/articles/PMC239893?pdf=render | ||
| P3181 | OpenCitations bibliographic resource ID | 5016554 |
| P932 | PMC publication ID | 239893 |
| P698 | PubMed publication ID | 14594454 |
| P5875 | ResearchGate publication ID | 9030168 |
| P50 | author | Carsten Gründker | Q104131351 |
| P2093 | author name string | Günter Emons | |
| P2860 | cites work | LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer | Q22254198 |
| Second gene for gonadotropin-releasing hormone in humans | Q24317742 | ||
| A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates | Q28188845 | ||
| A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12 | Q28204330 | ||
| Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation | Q28206472 | ||
| Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata | Q28342702 | ||
| A novel mammalian receptor for the evolutionarily conserved type II GnRH | Q28345646 | ||
| Involvement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase in alpha1B-adrenergic receptor/Galphaq-induced inhibition of cell proliferation | Q32126818 | ||
| The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary | Q34293507 | ||
| Biology of the gonadotropin-releasing hormone system in gynecological cancers | Q34467231 | ||
| Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone | Q35068355 | ||
| Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. | Q35614963 | ||
| Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species | Q36263472 | ||
| Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors | Q37412449 | ||
| Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation | Q37432455 | ||
| Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. | Q38298792 | ||
| Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. | Q38305783 | ||
| Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma | Q38316634 | ||
| Expression and signal transduction pathways of gonadotropin-releasing hormone receptors | Q40519029 | ||
| Hypothalamic hormones: from neuroendocrinology to cancer therapy. | Q40682650 | ||
| Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase | Q40805639 | ||
| Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers | Q40864187 | ||
| Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. | Q40887346 | ||
| Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. | Q40971129 | ||
| Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line | Q41097193 | ||
| Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice | Q41097702 | ||
| Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. | Q41105921 | ||
| The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. | Q41203834 | ||
| Growth inhibition of human prostate tumor cells by an agonist of gonadotrophin-releasing hormone | Q41354135 | ||
| Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). | Q41372843 | ||
| Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis | Q41496310 | ||
| Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium | Q41685614 | ||
| Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line | Q41703246 | ||
| The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors | Q41729614 | ||
| Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells | Q42498122 | ||
| Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors | Q42509019 | ||
| Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin | Q43807625 | ||
| Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells | Q44021000 | ||
| Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues | Q45712994 | ||
| Phosphotyrosine phosphatase-activity in membranes from endometrial carcinoma | Q47756941 | ||
| Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. | Q47763136 | ||
| Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. | Q47977493 | ||
| Effects of GnRH analogs on six ovarian cancer cell lines in culture | Q48094405 | ||
| Regional expression of mRNA encoding a second form of gonadotropin-releasing hormone in the macaque brain | Q48251675 | ||
| Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain | Q48324176 | ||
| Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. | Q53727336 | ||
| Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist | Q59065919 | ||
| Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata | Q69492544 | ||
| Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane | Q71079605 | ||
| Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines | Q71254335 | ||
| Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors | Q71477174 | ||
| Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145 | Q71788622 | ||
| Differentially regulated immediate early genes in the rat uterus | Q72315037 | ||
| High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines | Q72559548 | ||
| High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines | Q72662186 | ||
| The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers | Q72810392 | ||
| Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells | Q73148506 | ||
| Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors | Q73556567 | ||
| Regulation of UT-OC-3 ovarian carcinoma cells by cytokines: inhibitory effects on cell proliferation and activation of transcription factors AP-1 and NF-kappaB | Q73645052 | ||
| Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies | Q73936293 | ||
| Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone | Q77718861 | ||
| Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells | Q81066875 | ||
| Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice | Q84074281 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| endocrinology | Q162606 | ||
| hormone | Q11364 | ||
| peptide | Q172847 | ||
| reproductive medicine | Q351870 | ||
| nerve tissue protein | Q6996861 | ||
| ovarian neoplasm | Q11793790 | ||
| P304 | page(s) | 65 | |
| P577 | publication date | 2003-10-07 | |
| P1433 | published in | Reproductive Biology and Endocrinology | Q15767218 |
| P1476 | title | Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer | |
| P478 | volume | 1 |
| Q37170936 | Activin modulates the transcriptional response of LbetaT2 cells to gonadotropin-releasing hormone and alters cellular proliferation |
| Q38745095 | Applying Multivariate Adaptive Splines to Identify Genes With Expressions Varying After Diagnosis in Microarray Experiments |
| Q39952350 | Differential expression of ribosomal protein gene, gonadotrophin releasing hormone gene and Balbiani ring protein gene in silver nanoparticles exposed Chironomus riparius |
| Q40074140 | Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. |
| Q44834900 | Evidence for different gonadotropin-releasing hormone response sites in rat ovarian and pituitary cells |
| Q47221769 | Expression and Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Mammals |
| Q41760615 | Expression of gonadotropin-releasing hormone receptor and effect of gonadotropin-releasing hormone analogue on proliferation of cultured gastric smooth muscle cells of rats |
| Q93134519 | Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy |
| Q48166254 | Glucose regulates the intrinsic inflammatory response of the heart to surgically induced hypothermic ischemic arrest and reperfusion |
| Q38682630 | GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. |
| Q33663674 | GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor |
| Q37282095 | GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. |
| Q37311391 | Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. |
| Q38855783 | Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells |
| Q26751021 | Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations |
| Q48180834 | Inhibition of RM-1 prostate carcinoma and eliciting robust immune responses in the mouse model by using VEGF-M2-GnRH3-hinge-MVP vaccine |
| Q37584911 | Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides |
| Q47886786 | Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. |
| Q38980206 | LHRH-Targeted Drug Delivery Systems for Cancer Therapy. |
| Q39236911 | Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. |
| Q36256142 | Regulation of expression of mammalian gonadotrophin-releasing hormone receptor genes. |
| Q30983330 | Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. |
| Q37245459 | Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor |
| Q30438763 | The gonadotropin-releasing hormone (GnRH) neuronal population is normal in size and distribution in GnRH-deficient and GnRH receptor-mutant hypogonadal mice. |
| Q37098271 | Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog |
| Q37679148 | Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is It Protective? |
Search more.